This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read PaxMedica’s 8K filing here.
About PaxMedica
PaxMedica, Inc, a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome.
See Also
- Five stocks we like better than PaxMedica
- Why is the Ex-Dividend Date Significant to Investors?
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- Growth Stocks: What They Are, What They Are Not
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- Are Penny Stocks a Good Fit for Your Portfolio?
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
